Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer

NCT03785704 is registered in ClinicalTrials.gov with Peking Union Medical College as lead sponsor.

NCT NCT03785704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03785704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer
Lead sponsor
Peking Union Medical College
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2019
Completion date
March 1, 2025
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, cardiac event, chemotherapeutic toxicity